Thermo Fisher Scientific Ocrelizumab Recombinant Rabbit Monoclonal Antibody (15E7), MonoRab

Thermo Fisher Scientific Ocrelizumab Recombinant Rabbit Monoclonal Antibody (15E7), MonoRab

Applications

• ELISA (ELISA)

Tested Dilution: 0.01–1 µg/mL
Publications: - [References not provided]

Product Specifications

Product Specific Information

• Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
• Recommended dilutions:
  • Sandwich ELISA: 0.5–2 µg/mL
  • Competitive ELISA: 1–10 µg/mL
• Stability:
  • Lyophilized product stable up to 1 year at -20°C from date of receipt.
  • After reconstitution: 2–3 weeks at 2–8°C or up to 12 months at -20°C or below.
  • Avoid repeated freeze/thaw cycles.

Target Information

Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B lymphocytes expressing the CD20 antigen. As a humanized molecule, ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with relapsing or progressive forms of MS.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.